Manipulated immunoregulatory element and immunity altered thereby
AssigneeToolgen Incorporated
InventorsSeok Joong Kim, Yoon-Young Kim, Ho-Sung Yu, In-Young Jung, Jung Min Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGKα, DGKζ, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof
Claims13
-34. (canceled)
A guide RNA for manipulating human Dgkζ gene or a nucleic acid encoding the guide RNA,
- wherein the guide RNA comprises a guide domain, a first complementary domain, a linker domain, and a second complementary domain,
- wherein the guide domain has a guide sequence which consists of 1st to 20th nucleotide of SEQ ID NO:
- 111, in which each thymine of the guide sequence are changed to uracil.
A composition for manipulating immune regulatory gene, the composition comprising:
- a guide RNA for manipulating human Dgkζ gene or a nucleic acid encoding the guide RNA,
- wherein the guide RNA comprises a guide domain, a first complementary domain, a linker domain, and a second complementary domain,
- wherein the guide domain has a guide sequence which consists of 1st to 20th nucleotides of SEQ ID NO:
- 111, in which each thymine of the guide sequence are changed to uracil;
- and
- an editor protein or a nucleic acid encoding the editor protein, wherein the editor protein is a Streptococcus pyogenes-derived Cas9 protein.
A method for manipulating immune regulatory gene, the method comprising:
- contacting a guide RNA for manipulating human Dgkζ gene or a nucleic acid encoding the guide RNA and an editor protein or a nucleic acid encoding the editor protein with a human immune cell,
- wherein the guide RNA comprises a guide domain, a first complementary domain, a linker domain, and a second complementary domain,
- wherein the guide domain has a guide sequence which consists of 1st to 20th nucleotide of SEQ ID NO:
- 111, in which each thymine of the guide sequence are changed to uracil, and
- wherein the editor protein is a Streptococcus pyogenes-derived Cas9 protein.
Dependencies are inferred from the claim text.